3 results
Approved WMOPending
To evaluate the efficacy of BEM compared with placebo in reducing all cause hospitalization or all-cause death in COVID-19 outpatients receiving only supportive care.
Approved WMORecruiting
Primary Efficacy Objective:Primary objective: To evaluate if the addition of ISA101b to cemiplimab results in improved overall response rate (ORR) compared to cemiplimab alone, according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1…
Approved WMOCompleted
1) To assess uptake of [18F]BMS-986192 in tumor lesions before and after treatment with nivolumab, in relation to [18F]-FDG uptake as potential whole body biomarker for response. 2) To evaluate safety and tolerability of neoadjuvant nivolumab 3) To…